3 recruiting. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 3 |
| Phase 2 | 1 | Recruiting 1 |
Follow B-cell Acute Lymphoblastic Leukemia: new trials by email Literature Review of B-cell Acute Lymphoblastic Leukemia trials Research Report on B-cell Acute Lymphoblastic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) MK-1045, Blinatumomab, Acetaminophen - B-cell Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 340 | 2026-05-18 | 2026-11-10 |
| A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia Fludarabine, Cyclophosphamide, CAR-T - B-cell Acute Lymphoblastic Leukemia | Phase 3 | Recruiting | Memorial Sloan Kettering Cancer Center | 130 | 2025-10-20 | 2026-11-12 |
| Study of Out of Specification for Tisagenlecleucel CTL019 - B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma | Phase 3 | Recruiting | Novartis Pharmaceuticals | 200 | 2019-11-21 | 2026-09-15 |
Burkitt Lymphoma (3) · Lymphoma, Large B-Cell, Diffuse (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
DNA Virus Infections (3) · Epstein-Barr Virus Infections (3) · Hemic and Lymphatic Diseases (3) · Herpesviridae Infections (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Infections (3) · Lymphatic Diseases (3) · Lymphoma (3) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Tumor Virus Infections (3)
Acetaminophen (1) · Cyclophosphamide (1) · Dexamethasone (1) · Diphenhydramine (1) · blinatumomab (1) · fludarabine (1) · siltuximab (1) · tisagenlecleucel (1) · tocilizumab (1)
Memorial Sloan Kettering Cancer Center (1) · Merck Sharp & Dohme LLC (1) · Novartis Pharmaceuticals (1)
Canada (2) · Japan (2) · Netherlands (2) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Israel (1) · Italy (1) · Spain (1) · Sweden (1) · United States (1)
Kevin Curran, MD (1)
2025 (1)